ClinicalTrials.gg
RecruitingNCT07421700Updated Oct 8, 2026

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

A Phase 1/2 interventional study of PF-08634404 and Enfortumab Vedotin in Urothelial Cancer, Advanced/Metastatic Urothelial Cancer and Urothelial Carcinoma, sponsored by Pfizer. Recruiting at 184 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 8, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Carcinoma, Transitional Cell by Pfizer — 4 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Transitional Cell · Pfizer.

Started
2026
with 2 others
Phase 1/2
Only one
of the 14
Registered
13th of 14
by date

Among the 14 studies in Carcinoma, Transitional Cell by Pfizer, this one is one of 3 that started in 2026, is the only one in phase 1/2, and was the 13th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

4 of the 14 studies in Carcinoma, Transitional Cell by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Transitional Cell by Pfizer, or all of them as a file.
02

Study summary

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body.

The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer.

To join the study, participants must:

  • Be adults (18 years or older) and
  • Have locally advanced or metastatic urothelial cancer,

The study has two groups:

  • Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone.
  • Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin.

Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable.

Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer.

If the cancer gets worse but the treatment is still helping and side effects are manageable, participants may be allowed to continue treatment with their doctor's and the sponsor's agreement.

03

Conditions studied

  • Urothelial Cancer
  • Advanced/Metastatic Urothelial Cancer
  • Urothelial Carcinoma

Keywords

  • urothelial cancer
  • metastatic urothelial cancer
  • locally advanced urothelial cancer
  • bladder cancer
  • urothelial carcinoma
  • PD-1
  • VEGF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of screening.
  • confirmed locally advanced or urothelial carcinoma (LA/mUC).
  • per v1.1 criteria.
  • performance status of 0 or 1.
  • Adequate organ function, including hematologic, hepatic, and renal parameters.
  • Willingness to comply with study procedures and provide .
  • For participants of : agreement to use effective during the study and for a defined period after the last dose.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded if they meet any of the following:

  • History of another within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy
  • Known active CNS lesions, including , brainstem, meningeal, or spinal cord or compression
  • Active diseases requiring systemic treatment within the past 2 years
  • Participation in another study within 30 days or 5 half-lives of the investigational product.
  • Pregnant or breastfeeding individuals.
  • Inability or unwillingness to comply with study requirements.
  • Study staff or their immediate family members directly involved in the conduct of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Cohort A

    Participants with previously treated LA/mUC will receive PF-08634404 administered intravenously as monotherapy.

    Biological: PF-08634404

  • Experimental
    Cohort B

    Participants with untreated LA/mUC will receive PF-08634404 in combination with enfortumab vedotin

    Biological: PF-08634404 · Biological: Enfortumab Vedotin

Interventions

  • BiologicalPF-08634404

    Concentrate for solution for Infusion.

    Also known as: SSGJ-707

  • Powder for concentrate for solution for infusion

    Also known as: PF-08046042, ASG-22CE, PADCEV

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) by investigator

    ORR is defined as the proportion of participants in the analysis population having a BOR of confirmed CR or confirmed PR according to RECIST v1.1 as assessed by investigator.

    Time frame: Up to approximately 3 years

  2. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness and relationship to study intervention.

    Time frame: Through 90 days after the last study intervention; Up to approximately 3 years

  3. Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B

    The number of participants who experienced DLTs in participants receiving PF-08634404 in combination with EV.

    Time frame: Through 90 days after the last study intervention; Up to approximately 3 years

Secondary outcomes

  1. Duration of Response (DOR) per RECIST v1.1 by investigator

    DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

  2. Progression Free Survival (PFS) per RECIST v1.1 by investigator

    Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective PD assessed by investigator per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

  3. Overall Survival (OS)

    Overall survival defined as the time from the date of C1D1 to the date of death due to any cause.

    Time frame: Up to approximately 3 years

  4. Number of Participants With Clinical Laboratory Abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0)

    Time frame: Through 90 days after the last study intervention; Up to approximately 3 years

  5. Pharmacokinetics (PK): Serum concentration of PF-08634404

    To characterize the pharmacokinetics (PK) of PF-08634404 as monotherapy in participants with previously treated LA/mUC and in combination with EV in participants with previously untreated LA/mUC.

    Time frame: Up to 37 days after the last dose of treatment

  6. Incidence of Anti-Drug Antibody (ADA) against PF-08634404

    To evaluate the immunogenicity of PF-08634404 as monotherapy in participants with previously treated LA/mUC and in combination with EV in participants with previously untreated LA/mUC.

    Time frame: Up to 37 days after the last dose of treatment

07

Study locations

173 of 184 sites recruiting

Showing the first 100 of 184 sites across 6 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 47 phase 1/2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 224. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Dec 28, 2027
CompletionEst.
Sep 25, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
42 sites added, 11 sites removed. 22 sites changed recruiting status (22 now recruiting)
Show 22 sites
  • UCLA Hematology/Oncology - Alhambra · Alhambra, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Atascadero · Atascadero, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Beverly Hills · Beverly Hills, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Burbank · Burbank, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Encino · Encino, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Irvine · Irvine, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology Oncology- Laguna Hills · Laguna Hills, United StatesNot yet recruiting→Recruiting
  • (IRB# 26-0433) Ronald Reagan UCLA Medical Center, Drug Information Center · Los Angeles, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology · Los Angeles, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Marina del Rey · Marina del Rey, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Pasadena · Pasadena, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology Oncology - Porter Ranch · Porter Ranch, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - San Luis Obispo · San Luis Obispo, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology- Santa Barbara · Santa Barbara, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology- Santa Monica · Santa Monica, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Torrance · Torrance, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Santa Clarita · Valencia, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Ventura · Ventura, United StatesNot yet recruiting→Recruiting
  • UCLA Hematology/Oncology - Westlake · Westlake Village, United StatesNot yet recruiting→Recruiting
  • Hospital Universitari Vall d'Hebron · Barcelona, SpainNot yet recruiting→Recruiting
  • START Los Angeles, LLC · Los Angeles, United StatesNot yet recruiting→Recruiting
  • Los Angeles Cancer Network - Century City · Los Angeles, United StatesNot yet recruiting→Recruiting
Show 42 added (32 United States, 4 Japan, 4 Spain, 2 Puerto Rico)
  • Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United States
  • UCI Health - Irvine Infusion Pharmacy ACC · Irvine, United States
  • START Los Angeles, LLC · Los Angeles, United States
  • Los Angeles Cancer Network - Century City · Los Angeles, United States
  • UC Irvine Health · Orange, United States
  • Smilow Cancer Hospital - Derby · Derby, United States
  • Smilow Cancer Hospital - Fairfield · Fairfield, United States
  • Smilow Cancer Hospital - Greenwich · Greenwich, United States
  • Smilow Cancer Hospital - Guilford · Guilford, United States
  • Smilow Cancer Hospital - Yale New Haven Health · New Haven, United States
  • Yale Eye Center · New Haven, United States
  • Yale-New Haven Hospital-Yale Cancer Center · New Haven, United States
  • Smilow Cancer Hospital Phase 1 Unit · New Haven, United States
  • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP · New Haven, United States
  • Smilow Cancer Hospital - North Haven · North Haven, United States
  • Smilow Cancer Hospital - Long Ridge · Stamford, United States
  • Smilow Cancer Hospital - Trumbull · Trumbull, United States
  • Cleveland Clinic Foundation · Cleveland, United States
  • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy · Cleveland, United States
  • Texas Oncology - Central South · Weslaco, United States
  • Huntsman Cancer Institute - University of Utah · Salt Lake City, United States
  • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
  • Yamagata University Hospital · Yamagata, Japan
  • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen Del Rocio · Seville, Spain
  • MSK Basking Ridge · Basking Ridge, United States
  • MSK Monmouth · Middletown, United States
  • MSK Bergen · Montvale, United States
  • MSK Commack · Commack, United States
  • …and 12 more on the registry record
Show 11 removed
  • Texas Oncology - Central South · Austin, United States
  • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
  • Yamagata University Hospital · Yamagata, Japan
  • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen Del Rocio · Seville, Spain
  • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
  • Yamagata University Hospital · Yamagata, Japan
  • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen Del Rocio · Seville, Spain
across 2 updates, Sep 28, 2026 – Oct 8, 2026
Primary completion
Dec 6, 2027→Dec 28, 2027
Sep 28, 2026
Study completion
Sep 5, 2028→Sep 25, 2028
Sep 28, 2026
Show all 2 updates
  1. Oct 8, 2026
    16 sites added, 5 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • START Los Angeles, LLC · Los Angeles, United StatesNot yet recruiting→Recruiting
    • Los Angeles Cancer Network - Century City · Los Angeles, United StatesNot yet recruiting→Recruiting
    Show 16 added (11 United States, 2 Japan, 2 Spain, 1 Puerto Rico)
    • MSK Basking Ridge · Basking Ridge, United States
    • MSK Monmouth · Middletown, United States
    • MSK Bergen · Montvale, United States
    • MSK Commack · Commack, United States
    • MSK Westchester · Harrison, United States
    • Investigational Drug Service · Long Island City, United States
    • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). · New York, United States
    • Evelyn H. Lauder Breast and Imaging Center (BAIC) · New York, United States
    • Memorial Sloan Kettering Cancer Center-Main Campus · New York, United States
    • Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center · New York, United States
    • MSK Nassau · Uniondale, United States
    • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
    • Yamagata University Hospital · Yamagata, Japan
    • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    Show 5 removed
    • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
    • Yamagata University Hospital · Yamagata, Japan
    • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Sep 28, 2026
    26 sites added, 6 sites removed. 20 sites changed recruiting status (20 now recruiting)
    Show 20 sites
    • UCLA Hematology/Oncology - Alhambra · Alhambra, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Atascadero · Atascadero, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Beverly Hills · Beverly Hills, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Burbank · Burbank, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Encino · Encino, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Irvine · Irvine, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology Oncology- Laguna Hills · Laguna Hills, United StatesNot yet recruiting→Recruiting
    • (IRB# 26-0433) Ronald Reagan UCLA Medical Center, Drug Information Center · Los Angeles, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology · Los Angeles, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Marina del Rey · Marina del Rey, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Pasadena · Pasadena, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology Oncology - Porter Ranch · Porter Ranch, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - San Luis Obispo · San Luis Obispo, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology- Santa Barbara · Santa Barbara, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology- Santa Monica · Santa Monica, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Torrance · Torrance, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Santa Clarita · Valencia, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Ventura · Ventura, United StatesNot yet recruiting→Recruiting
    • UCLA Hematology/Oncology - Westlake · Westlake Village, United StatesNot yet recruiting→Recruiting
    • Hospital Universitari Vall d'Hebron · Barcelona, SpainNot yet recruiting→Recruiting
    Show 26 added (21 United States, 2 Japan, 2 Spain, 1 Puerto Rico)
    • Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United States
    • UCI Health - Irvine Infusion Pharmacy ACC · Irvine, United States
    • START Los Angeles, LLC · Los Angeles, United States
    • Los Angeles Cancer Network - Century City · Los Angeles, United States
    • UC Irvine Health · Orange, United States
    • Smilow Cancer Hospital - Derby · Derby, United States
    • Smilow Cancer Hospital - Fairfield · Fairfield, United States
    • Smilow Cancer Hospital - Greenwich · Greenwich, United States
    • Smilow Cancer Hospital - Guilford · Guilford, United States
    • Smilow Cancer Hospital - Yale New Haven Health · New Haven, United States
    • Yale Eye Center · New Haven, United States
    • Yale-New Haven Hospital-Yale Cancer Center · New Haven, United States
    • Smilow Cancer Hospital Phase 1 Unit · New Haven, United States
    • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP · New Haven, United States
    • Smilow Cancer Hospital - North Haven · North Haven, United States
    • Smilow Cancer Hospital - Long Ridge · Stamford, United States
    • Smilow Cancer Hospital - Trumbull · Trumbull, United States
    • Cleveland Clinic Foundation · Cleveland, United States
    • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy · Cleveland, United States
    • Texas Oncology - Central South · Weslaco, United States
    • Huntsman Cancer Institute - University of Utah · Salt Lake City, United States
    • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
    • Yamagata University Hospital · Yamagata, Japan
    • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    Show 6 removed
    • Texas Oncology - Central South · Austin, United States
    • National Hospital Organization Kyushu Cancer Center · Fukuoka, Japan
    • Yamagata University Hospital · Yamagata, Japan
    • Pan American Center for Oncology Trials, LLC - Manati Office · Manati, Puerto Rico
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    Primary completion Dec 6, 2027→Dec 28, 2027
    Study completion Sep 5, 2028→Sep 25, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07421700
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Mar 11, 2026
Primary completion
Dec 28, 2027 (estimated)
Completion
Sep 25, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404

Start the discussion